To control the worsening situation of Corona in the country, the entire staff of the government has gathered. In the war against Corona Pandemic, the government, army, and common people are also playing their part. The DRDO had also engaged its scientists to deal with the corona and to research the medicine on the first day. After almost a year of research and clinical trials, the Institute of Nuclear Medicine and Allied Sciences (INMAS) has developed the anti-covid-19 drug 2-deoxy-D-glucose (2-DG) in collaboration with Dr Reddy’s Laboratories. In view of the worsening conditions of the coronavirus in the country, the Drugs Controller General of India has used the drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy for severe COVID-19 patients. The 2-deoxy-D-glucose drug made by DRDO is believed to be a panacea to prevent the corona from spreading. INMAS scientist Dr. Sudhir Chandna said that this drug is completely safe and said that it will help patients to recover quickly. After a successful trial, this drug will be first given in the DRDO Covid Hospital of Delhi. According to sources, in the next one or two days, 2 DGs will be sent to the hospital for treatment of corona victims. According to DRDO scientists, this drug will be in the form of a powder, which will also be very easy to use.
Drug results have been found effective
2-DG is developed by INMAS in collaboration with Dr. Reddy’s Laboratories (DRL) of Hyderabad. INMAS is a lab of the Defense Research and Development Organization (DRDO). Dr. Chandana, the scientist of this lab, has told about this drug, ‘In clinical trials, this drug has given effective results in curing patients infected with COVID-19. Clinical trials of this drug have been done on about 110 patients in the second phase and 220 patients in the third phase. This led to the recovery of patients in 2-3 days. Not only this, the oxygen of patients was also quickly removed.
He further said that in the third phase, 42 percent of the patients did not have to apply oxygen from the third day onwards. Obviously, this data suggests that if we use this medicine in standard care then the dependence on oxygen can be reduced considerably.
Trials started last year
DRDO, along with its industry partner DRL, started clinical trials for this drug in April last year. Phase II trials were conducted from May to October 2020 on 110 patients. Later Phase III trials took place between December 2020 to March 2021. Regarding the price of this drug, Dr. Chandana said that it will depend on the factors of production of the drug and our partnership with DRL. According to our information, it will be known soon.
How was 2-DG developed? How were clinical trials conducted?
DRDO Project Director and Scientist of 2-DG, Dr. Sudhir Chandana clarified how the medication was created. He expressed that when the pandemic hit India in April 2020, they found that 2-DG ends the spread of COVID-19 inside the body cells. “After the discoveries, we asked the DCGI for authorization to lead clinical preliminaries. In May 2020, we got consent for the clinical preliminaries. Before the finish of October 2020, we had finished the second period of preliminaries, and the outcomes were excellent. Utilizing standard consideration, 2 DG will be more useful for the Covid-19 patients,” Chandana told News18.
An aggregate of 110 patients was important for the Phase-II clinical preliminaries of DRDO’s 2-DG drug. The outcomes showed that as far as the progress of fundamental indications of COVID-19 suggestive patients there was a distinction of 2.5 days contrasted with Standard of Care (SoC). Endorsement for Phase – III clinical preliminaries were conceded in November 2020. These were directed in 27 COVID-19 clinics spread across a few states. “Clinical preliminary outcomes have shown that this atom helps in quicker recuperation of hospitalized patients and lessens supplemental oxygen reliance,” an authority DRDO articulation had clarified before.
How 2-DG controls COVID-19 and reduces dependence on oxygen?
Clarifying how 2-DG controls COVID-19 and diminishes reliance on oxygen, Chandana told the new channel, “The 2 DG drug, similar to glucose, spreads through the body, arrives at the infection-tainted cells and forestalls infection development by halting viral combination and obliterates the protein’s energy creation. The medication additionally chips away at infection disease spread into lungs which assist us with diminishing patients steadfastness on oxygen”.
How might 2-DG be fabricated?
The DRDO expressed that the 2-deoxy-D-glucose (2-DG) medication can without much of a stretch be delivered in India and made accessible in a lot to the residents as it is a nonexclusive particle and simple of glucose.
How is 2-DG be burned-through?
The counter COVID drug 2-DG has been created in powder structure and is ingested orally by dissolving it in water.